Paula Ragan
Known title: President and CEOCIK: 0001769914
Associated companies
Transaction History
| XFOR | ▲ Buy | Grant | 2,250,000 | $0 | 2/12/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 76,473 | $35K | 1/24/2025 | View on chart |
| XFOR | ▲ Buy | Grant | 169,940 | $0 | 1/23/2025 | View on chart |
| XFOR | ▼ Sell | Open Market | 31,897 | $13K | 11/15/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 31,897 | $18K | 10/15/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 239,436 | $132K | 10/7/2024 | View on chart |
| XFOR | ▲ Buy | Grant | 532,081 | $0 | 10/4/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 49,678 | $44K | 3/11/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 21,695 | $22K | 2/12/2024 | View on chart |
| XFOR | ▼ Sell | Open Market | 39,906 | $36K | 11/3/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 199,531 | $146K | 11/1/2023 | View on chart |
| XFOR | ▲ Buy | Grant | 532,081 | $0 | 10/31/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,724 | $13K | 6/23/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,724 | $15K | 6/15/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,292 | $12K | 5/31/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 49,678 | $42K | 3/10/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 21,695 | $20K | 2/13/2023 | View on chart |
| XFOR | ▼ Sell | Open Market | 13,448 | — | 8/17/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,724 | — | 6/24/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,724 | — | 6/16/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 6,292 | $8K | 6/3/2022 | View on chart |
| XFOR | ▲ Buy | Grant | 220,789 | $0 | 3/1/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 21,695 | — | 2/11/2022 | View on chart |
| XFOR | ▼ Sell | Open Market | 13,448 | $69K | 8/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround
X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.
X4 Pharmaceuticals (XFOR) Faces 25% Drop, Possible Turnaround. X4 Pharmaceuticals has fallen 25.4% in the past month, but a Yahoo article highlights factors that could spark a rebound. Analysts point to recent revenue growth and a volume spike that suggest increased demand. With an RSI of 27.1 and support at $4.00, the stock may be primed for a move back toward its 52‑week range.